Max Chat
USANA Health Sciences
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
7/10
|
16.09 | 24.22 | -33.56% | 15.62 | +3% |
| P/S |
|
0.7914 | 2.61 | -69.64% |
|
|
| P/BV |
|
1.15 | 14.84 | -92.23% |
|
|
| P/FCF |
|
23.96 | 20.6 | 16.32% |
|
|
| Ev/Ebitda |
|
5.23 | 14.45 | -63.79% |
|
|
| Ev/S |
|
0.6056 | 3.1 | -80.48% |
|
|
| Ev/FCF |
|
10.16 | 28.75 | -64.65% |
|
|
| E/P |
|
0.0345 | 0.1727 | -80.02% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
4/10
|
11.57 | 20.36 | -43.17% | 12.75 | -9.28% |
| ROE |
|
8.17 | 59.71 | -86.32% |
|
|
| ROA |
|
6.09 | 8.94 | -31.9% |
|
|
| ROIC |
|
26.26 | 15.48 | 69.59% |
|
|
| ROS |
|
4.92 | 11.28 | -56.37% |
|
|
| ROCE |
|
13.07 | 88.1 | -85.17% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.2326 | 2.86 | -91.87% | 0.1335 | +74.25% |
| Nеt Debt/Ebitda |
|
-1.61 | 2.56 | -162.61% |
|
|
| Debt/Ratio |
|
0.0307 | 0.3954 | -92.23% |
|
|
| Debt/Equity |
|
0.2761 | 4.05 | -93.18% |
|
|
| Debt/Net Income |
|
0.5472 | 6.44 | -91.5% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 3.07 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 11.29 | -100% | ||
| DSI |
|
0 | 0.9388 | -100% |
|
|
| Average dividend growth |
|
0 | 1.51 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.92 | -100% |
|
|
| Average percentage for payments |
|
55.72 | 62.49 | -10.83% |
|
|
| Difference from average difference in sector |
|
-3.07 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-24.38 | 1081.18 | -102.25% | ||
| Growth impulse Ebitda in 5 years |
|
-43.99 | 1127.57 | -103.9% | ||
| Growth impulse Net Income in 5 years |
|
-66.3 | 1273.27 | -105.21% | ||
| Growth impulse FCF in 5 years |
|
-64.96 | 525.9 | -112.35% | ||
| Growth impulse EPS in 5 years |
|
-62.57 | 669.62 | -109.34% |
IP Score
4.66/10
